Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.7 USD | +1.07% | -5.21% | +12.20% |
05-13 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
05-10 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.20% | 1.65B | |
+8.08% | 113B | |
+10.22% | 106B | |
+0.41% | 22.27B | |
-12.13% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.94% | 17.24B | |
+7.26% | 14.29B | |
+36.63% | 12.52B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment